about
Antisense oligonucleotides: treating neurodegeneration at the level of RNARegulating gene expression with light-activated oligonucleotides.Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.Ultrasmall gold nanoparticles as carriers for nucleus-based gene therapy due to size-dependent nuclear entryMetallothioneins and zinc in cancer diagnosis and therapy.Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection.Antisense-based cancer therapeutics: are we there yet?Antisense oligonucleotides: from design to therapeutic application.Recent advances in delivery systems for anti-HIV1 therapy.Development of TLR9 agonists for cancer therapyThe delivery of therapeutic oligonucleotidesBiological barriers to therapy with antisense and siRNA oligonucleotides.Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.A generalizable pre-clinical research approach for orphan disease therapyInfluence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.Preclinical development of therapeutic biologics.Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.Enhancement of in vitro translation by gold nanoparticle--DNA conjugates.New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.Silencing genes in the kidney: antisense or RNA interference?The balance of Polo-like kinase 1 in tumorigenesis.Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice.Resurrecting DNAzymes as sequence-specific therapeutics.Toxicology in the drug discovery and development process.The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.
P2860
Q27007056-54494DEC-0081-4927-BDC3-93B43ACED224Q33270099-4EACDBFA-C484-457D-88C8-F1C61074047AQ33392841-C0A996E8-4407-4A40-8C41-1D90DBEB5991Q33809839-9F1C4998-FFD5-4A8B-B7E9-2EE9159AB09DQ33824831-F1B4E394-0363-4E1C-8AB7-48D6F6552B21Q34643692-0C134CD3-96DF-4701-9F41-A19B7E8582BAQ35113870-C5054552-6365-4440-9D90-8721391840CBQ35159206-3145FCE0-C0C7-4D7D-B288-3B905DB6C446Q36458427-3758C3D3-D815-4BF3-8AB7-8B295F0F932AQ36478849-9763F6B8-C7B9-46D6-9F0B-3AB999D0F2E5Q36761854-6A0DD52F-2889-4F45-8705-28A87190933AQ36809776-7342BA7E-DA43-4D12-A331-9EEDC43616C6Q37210936-2FA2E05B-1ACC-4160-9B42-7CA709104E4AQ37378340-00F3C8A3-83D4-4178-A6B0-3B7327160653Q37588723-6FC3CEE7-83BB-482F-9EBC-7B891384B8F1Q37628708-C2C036F2-6381-4178-A318-16F19DF988F5Q38019219-17BB49CE-491F-4C98-8EA2-20723C4323CDQ38085679-1B9C3C5D-7DE5-440E-82A8-A52472F6DEEEQ38088310-E8A158DF-CEFC-4C99-B3C3-3149E79AEA36Q38504825-FDD67050-EA0A-4F36-939D-6AD2A2196791Q40005854-3890AA24-8584-4E30-86BF-5063BBFEE147Q40745399-2A7D3F74-25A0-4F39-9BB4-2D9EE6495722Q42153007-B0D6B4B1-0732-4E11-A622-A1556349C678Q43061873-6AF5F3C3-13E5-436D-936D-BF0ADBF30415Q43180721-93F698BD-8BEC-4B7B-A254-0C9D38C93944Q46092877-F7058E9E-0E30-4A80-837D-C11CBE8F123AQ47567258-43FA05F1-DBEC-42CE-92CB-7ADC2EC83B37Q53347876-92D973A5-9751-4D8B-835D-1373D79BC91FQ55356724-A74080F5-B743-4EEC-840B-729C03C7E2B3
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Toxicology of antisense therapeutics.
@ast
Toxicology of antisense therapeutics.
@en
type
label
Toxicology of antisense therapeutics.
@ast
Toxicology of antisense therapeutics.
@en
prefLabel
Toxicology of antisense therapeutics.
@ast
Toxicology of antisense therapeutics.
@en
P2093
P1476
Toxicology of antisense therapeutics.
@en
P2093
James Koropatnick
Randal W Berg
Tracey L H Jason
P356
10.1016/J.TAAP.2004.04.017
P577
2004-11-01T00:00:00Z